News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
286,603 Results
Type
Article (15557)
Company Profile (102)
Press Release (270935)
Multimedia
Podcasts (119)
Webinars (14)
Section
Business (90913)
Career Advice (504)
Deals (15902)
Drug Delivery (116)
Drug Development (38044)
Employer Resources (51)
FDA (6827)
Job Trends (6545)
News (155600)
Policy (14728)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (485)
Accelerated approval (21)
Adcomms (12)
Allergies (89)
Alliances (23938)
ALS (71)
Alzheimer's disease (550)
Antibody-drug conjugate (ADC) (159)
Approvals (7084)
Artificial intelligence (268)
Autoimmune disease (74)
Automation (18)
Bankruptcy (157)
Best Places to Work (4605)
BIOSECURE Act (10)
Biosimilars (146)
Biotechnology (41)
Bladder cancer (50)
Brain cancer (40)
Breast cancer (212)
Cancer (1676)
Cardiovascular disease (241)
Career advice (446)
Career pathing (14)
CAR-T (64)
CDC (10)
Cell therapy (202)
Cervical cancer (16)
Clinical research (33416)
Collaboration (941)
Compensation (369)
Complete response letters (51)
COVID-19 (825)
CRISPR (49)
C-suite (591)
Cystic fibrosis (64)
Data (2397)
Decentralized trials (2)
Denatured (20)
Depression (57)
Dermatology (12)
Diabetes (259)
Diagnostics (1572)
Digital health (16)
Diversity (4)
Diversity, equity & inclusion (15)
Drug discovery (152)
Drug pricing (174)
Drug shortages (32)
Duchenne muscular dystrophy (94)
Earnings (34845)
Editorial (36)
Employer branding (4)
Employer resources (48)
Events (40808)
Executive appointments (603)
FDA (8263)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (2)
Frontotemporal dementia (4)
Funding (583)
Gene editing (83)
Generative AI (31)
Gene therapy (218)
GLP-1 (876)
Government (1589)
Grass and pollen (4)
Guidances (181)
Healthcare (4034)
HIV (16)
Huntington's disease (10)
IgA nephropathy (46)
Immunology and inflammation (92)
Immuno-oncology (26)
Indications (81)
Infectious disease (916)
Inflammatory bowel disease (84)
Inflation Reduction Act (12)
Influenza (29)
Intellectual property (128)
Interviews (64)
IPO (6151)
IRA (44)
Job creations (2133)
Job search strategy (398)
JPM (40)
Kidney cancer (10)
Labor market (33)
Layoffs (240)
Leadership (11)
Legal (3564)
Liver cancer (26)
Longevity (9)
Lung cancer (227)
Lymphoma (146)
Machine learning (15)
Management (18)
Manufacturing (571)
MASH (101)
Medical device (1735)
Medtech (1747)
Mergers & acquisitions (10265)
Metabolic disorders (964)
mRNA (71)
Multiple sclerosis (57)
NASH (17)
Neurodegenerative disease (121)
Neuropsychiatric disorders (51)
Neuroscience (1065)
Neurotech (1)
NextGen: Class of 2026 (1781)
Non-profit (695)
Now hiring (45)
Obesity (589)
Opinion (158)
Ovarian cancer (63)
Pain (133)
Pancreatic cancer (73)
Parkinson's disease (100)
Partnered (12)
Patents (257)
Patient recruitment (169)
Peanut (15)
People (30714)
Pharmaceutical (60)
Pharmacy benefit managers (20)
Phase 1 (8662)
Phase 2 (14084)
Phase 3 (12752)
Pipeline (3066)
Policy (188)
Postmarket research (1437)
Preclinical (3500)
Press Release (25)
Prostate cancer (101)
Psychedelics (24)
Radiopharmaceuticals (156)
Rare diseases (469)
Real estate (2775)
Recruiting (19)
Regulatory (11789)
Reports (17)
Research institute (618)
Resumes & cover letters (65)
Rett syndrome (11)
RNA editing (11)
RSV (24)
Schizophrenia (86)
Series A (128)
Series B (70)
Service/supplier (2)
Sickle cell disease (62)
Special edition (11)
Spinal muscular atrophy (92)
Sponsored (11)
Startups (1722)
State (2)
Stomach cancer (6)
Supply chain (79)
Tariffs (79)
The Weekly (96)
Vaccines (277)
Venture capital (50)
Weight loss (455)
Women's health (45)
Worklife (4)
Date
Today (70)
Last 7 days (253)
Last 30 days (1032)
Last 365 days (11278)
2026 (3739)
2025 (11511)
2024 (13254)
2023 (14855)
2022 (20249)
2021 (20826)
2020 (19823)
2019 (15761)
2018 (12464)
2017 (14459)
2016 (13595)
2015 (15930)
2014 (12760)
2013 (10885)
2012 (11719)
2011 (12270)
2010 (11151)
Location
Africa (335)
Alabama (21)
Alaska (4)
Arizona (85)
Arkansas (5)
Asia (21500)
Australia (2873)
California (3828)
Canada (1726)
China (689)
Colorado (171)
Connecticut (151)
Delaware (154)
Europe (43594)
Florida (718)
Georgia (73)
Hawaii (1)
Idaho (11)
Illinois (426)
India (64)
Indiana (291)
Iowa (4)
Japan (319)
Kansas (80)
Kentucky (22)
Louisiana (8)
Maine (2)
Maryland (493)
Massachusetts (3064)
Michigan (67)
Minnesota (198)
Mississippi (1)
Missouri (38)
Montana (9)
Nebraska (12)
Nevada (18)
New Hampshire (12)
New Jersey (1725)
New Mexico (7)
New York (1073)
North Carolina (708)
North Dakota (2)
Northern California (1773)
Ohio (95)
Oklahoma (7)
Oregon (19)
Pennsylvania (828)
Puerto Rico (29)
Rhode Island (21)
South America (590)
South Carolina (12)
Southern California (1686)
Tennessee (68)
Texas (549)
United States (15136)
Utah (66)
Virginia (202)
Washington D.C. (43)
Washington State (284)
West Virginia (1)
Wisconsin (48)
Wyoming (1)
286,603 Results for "novo nordisk pharmaceuticals puerto rico".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Sickle cell disease
Novo’s late-stage sickle cell win piles pressure on competitors
Novo Nordisk’s etavopivat elicited a 27% drop in vaso-occlusive crises and 48.7% hemoglobin response after 24 weeks, creating “separation amongst PK class candidates,” Truist analysts said on Monday. Novo plans to seek FDA approval in the back half of 2026.
April 20, 2026
·
2 min read
·
Tristan Manalac
Manufacturing
Lilly Continues Manufacturing Push With $1.2B Puerto Rico Facility for GLP-1 Pill
The investment, which will expand Eli Lilly’s existing campus in Puerto Rico, is slated to create 100 new jobs, on top of around 1,000 construction-related roles.
October 30, 2025
·
2 min read
·
Tristan Manalac
Obesity
Boehringer, Zealand’s obesity drug ‘more akin’ to Novo’s Wegovy in Phase 3
Topline Phase 3 results of survodutide—licensed to Boehringer Ingelheim from Zealand Pharma—are more comparable to Novo Nordisk’s Wegovy than to Eli Lilly’s Zepbound, William Blair analysts said on Tuesday.
April 28, 2026
·
2 min read
·
Heather McKenzie
Press Releases
PharmaEssentia Signs Investment Agreement for New Manufacturing Facility in Puerto Rico
April 2, 2026
·
6 min read
GLP-1
Lilly’s Foundayo reaches 1,390 patients in first week, trailing Novo’s oral Wegovy launch
While Novo Nordisk’s Wegovy pill reached more than 3,000 patients in its first week on the market, analysts at RBC Capital Markets said a direct comparison of the two figures could be misleading given the shorter data collection time for Foundayo.
April 17, 2026
·
1 min read
·
Tristan Manalac
Layoffs
Layoffs at Novo’s Ex-Catalent Site Despite Signs of Turnaround, Continued Investment
As Novo Nordisk cuts 400 jobs at the troubled site, Scholar Rock has seen enough progress that it included the facility in a resubmission for FDA approval.
April 1, 2026
·
2 min read
·
Nick Paul Taylor
Obesity
Novo may have muscle advantage over Lilly in weight-loss race: preprint
More patients on Eli Lilly’s tirzepatide lost over 5% of their lean mass versus those on Novo Nordisk’s semaglutide, according to a study that has yet to be peer reviewed.
April 17, 2026
·
2 min read
·
Tristan Manalac
Earnings
Novo Holdings’ Assets Fell 34% in 2025 As Its Namesake Drugmaker Struggled
Total assets under management for Novo Holdings, Novo Nordisk’s controlling shareholder, fell by more than one-third last year. The report caps off a tumultuous year for the Novo group of companies.
March 12, 2026
·
1 min read
·
Annalee Armstrong
GLP-1s
Novo Nordisk Agrees To Sell GLP-1 Drugs Via Hims & Hers, Ending Dispute
The companies have been embroiled in a row about compounded GLP-1 drugs that escalated to a lawsuit last month. The legal action has now been dropped and the former adversaries have struck a deal that could increase access to Novo’s obesity medicines.
March 9, 2026
·
2 min read
·
Nick Paul Taylor
Approvals
Eli Lilly’s Oral Obesity Pill Approved, Kicking Off Renewed Novo Rivalry
The FDA approved Eli Lilly’s orforglipron—to be known as Foundayo—on Wednesday, officially igniting what analysts believe will be a fierce rivalry with Novo Nordisk’s oral Wegovy.
April 1, 2026
·
3 min read
·
Heather McKenzie
1 of 28,661
Next
